News

Sarepta Refused FDA’s Request to Halt Elevidys Shipments
Sarepta Therapeutics Inc. has refused to pause all shipments of its Elevidys treatment after three deaths were linked to the ...
GEN - Genetic Engineering and Biotechnology News2d
StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies
The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...
Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
STAT2y
FDA approval of Sarepta Duchenne genetic therapy gives me hope
If Sarepta's gene therapy SRP-9001 succeeded through ... FDA grants conditional approval to Sarepta’s gene therapy for Duchenne muscular ... It may be hard to know what impact it ...
Nasdaq2y
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne ...
--Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today announced twenty recipients of Route 79, The Duchenne Scholarship Program for the 2022-2023 academic ...
Seeking Alpha10mon
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79 ...
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year Sep. 05, 2024 9:00 AM ET Sarepta Therapeutics, Inc. (SRPT) ...